AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ENDRA Life Sciences Inc. Director's Dealing 2017

May 23, 2017

35444_dirs_2017-05-23_7b15bdeb-1d42-47fc-97ae-2492fcd41612.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-12

Reporting Person: Harsh Michael (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-12	Stock Options	$5.00	A	6000	Acquired	2025-05-12	Common Stock (6000)	Direct
2017-05-12	Stock Options	$5.00	A	6000	Acquired	2025-05-12	Common Stock (6000)	Direct

Footnotes

F1: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The
correct expiration date is May 12, 2025.

F2: This amendment is being filed to correct the exercisable date of these Stock Options, which was inadvertantly reported as May 12, 2017. The correct exercisable date is December 31, 2017.